NEW YORK (GenomeWeb) – German firm Cytena announced today that it has raised €3 million ($3.4 million) in a Series A financing round.
The firm will use the funding to expand its sales activities, as well as further develop and explore potential applications for its single-cell printer lab technology.
Founded in 2014 as a spin-off from the University of Freiburg's Institute for Microsystems Technology, Cytena has developed single-cell printer technology that allows single cell isolation for genomics research and clonal cell line development for biopharmaceutical production.
The funding round included High-Tech Gründerfonds and two private investment groups.
"The technological advantage of our single-cell printers over competing products does not mean that we can rest on our laurels," Cytena CFO Benjamin Steimle said in a statement. "Rather, our goal is to better understand and serve our customers needs."